THERE is extensive documentation of the antitumour effect of Corynebacterium parvum on a wide variety of solid and ascitic murine tumours (Woodruff and Boak, 1966; Halpern et al., 1966; Castro, 1974) and on its inhibitory effect on naturally occurring metastases (Proctor, Rudenstam and Alexander, 1973; Castro, 1975, 1976) .
In a pilot study of C. parvum treatment for patients with malignant disease, 2 of 10 patients developed de novo cerebral metastases, 5 and 9 months after starting regular monthly infusions of C. parvum, despite control of disease at other sites (Castro and Osborn, in press). At present there is no information on the effect of C. parvum on intracerebral (i.c.) tumour growth. C. parvum is considered to act by non-specific potentiation of the host's immune response (Scott, 1974a) and it is possible that i.c. tumours are protected from destruction by immunological mechanisms by the blood-brain barrier (Holman, 1972; Medawar, 1948) .
The aim of this study in mice was to determine the effect of parenteral C.
parvum on both the growth of i.c. inoculated tumours and the induction of i.c. tumour by methylcholanthrene.
MATERIALS AND METHODS
Animals.-Age-matched adult male BALB/c and female C57BL/10 Sc Sn were obtained from Olac (Southern) Ltd.
Corynebacterium parvum.-A formalinkilled suspension of C. parvum (Wellcome, strain CN 6134, batch PX 374, 7 mg dry weight/ml) was injected i.v. as a dose of 0-466 mg diluted with normal saline to 0-2 ml, i.p. or s.c. as 0 7 mg in 0 1 ml of undiluted solution. Control groups received an equal volume of saline.
Tumours.-A methylcholanthrene-induced sarcoma (Meth A) first described by Old et al. (1962) was used. It was maintained in ascitic form by weekly passage of 0.1 ml of malignant ascites into recipient BALB/c mice. It is syngeneic for BALB/c, antigenic and exhibits a good dose-response curve.
The Lewis lung carcinoma was grown in C57BL mice. It originated as a spontaneous epidermoid lung carcinoma in a female C57BL mouse in 1951 (Sugiura and Stock, 1955) (Courtenay, 1976) . Cell viability was determined with trypan blue.
The lungs of mice which had died after i.c. injection of Lewis tumour cells were inspected for macroscopic surface metastases, after staining by infusing the trachea with a dilute solution of Indian ink and fixing in Fekete's solution (Wexler, 1966) .
Intracerebral injection. Tumour cells were suspended in 0 01 -ml aliquots of medium TC199. Injection was made by hand into the right parietal region of ether-anaesthetized mice. A 25-gauge sleeved needle was employed to ensure uniform penetration to 3 mm (Albright et al., 1975) . The technique was rapid and easy, but there was an immediate mortality of approximately 500. The survival times of the mice were recorded.
Induction of tumour.-Cubes of methylcholanthrene were made by placing crystalline 20-methylcholanthrene (Sigma) in a test tube, and heating it over a Bunsen until it had liquefied. The liquid was poured into a Petri dish and allowed to solidify. The methyleholanthrene was then broken into small pieces. A 1-mm cube of methyleholanthrene was implanted into ether-anaesthetized BALB/c mice either s.c. in the upper dorsum or i.c. through a burr hole made with a dental drill in the right parietal region. Mice with s.e. implants were killed when the tumour was 1 cm in diameter, and those with i.c. implants when neurological signs of tumour were observed. The brains of all mice which had died from i.c. tumour were excised, fixed in formal saline and examined histologically after staining with haematoxylin and eosin. (Proctor et al., 1973; Sadler and Castro, 1976) . However, in a small clinical study of C. parvum therapy, 2 of 10 patients developed brain metastases, despite control of peripheral disease (Castro and Osborn (in prepn.) ). Therefore, an investigation was made into the effects of C. parvum on i.c. tumour in mice. In the absence of an available tumour which metastasized to the brain, 2 non-brain tumours were chosen for this study (Meth A, a methylcholanthreneinduced sarcoma, and Lewis lung carcinoma) and low doses of these were injected i.c. The action of C. parvum on the induction of s.c. and i.c. tumour by methylcholanthrene was also studied.
The responses of cerebral neoplasms to C. parvum may differ from those shown by systemic tumours because of the blood-brain barrier (Holman, 1972) . The brain lacks a network of lymphatic drainage (Humphrey and White, 1970) and therefore antigen must reach the lymphoid tissues primarily via the bloodstream or must await wandering macrophages and lymphocytes to enter the CNS. We found that the number of cells required for i.c. tumour growth was much lower than that required for successful s.c. growth, suggesting that this site was indeed immunologically privileged. However, there is evidence to suggest that, in the brain, inefficient antigen presentation to the immune system may result in a poor immunological response, rather than a decreased ability of antibody or sensitized lymphocytes to enter the brain (Levy, Mahaley, and Day, 1972; Hellstrom et al., 1968; Medawar, 1948; Denlinger et al., 1975) .
J.v. C. parvum was able to cause a slight but significant increase in the survival of mice with i.c. Meth A cells, but only if as few as 50 Meth A cells had been injected. C. parvum was effective if administered at the same time as tumour and there was some response if it was given up to 5 days later, but there was no effect once the tumour was established. Multiple i.v. injections were found to be no more effective than a single one. A similar result has been reported for s.c. tumour (Scott, 1974b) . However, there is no doubt that Meth A tumour is sensitive to C. parvum when grown at other sites (Castro, 1974) . C. parvum was found to have no influence on the survival of mice given i.c. Lewis tumour despite previous observations in this laboratory that both the primary s.c. tumour and its metastases are inhibited by C. parvum Castro, 1975, 1976) . Neither was there any significant effect on the induction of s.c. or i.c. tumour by methylcholanthrene. This last result is in contrast to the studies of Baum and Baum (1974) who reported an increased delay in the induction of sarcomas by methylcholanthrene after C. parvum treatment. Thus, C. parvum therapy was found to be of little use in the treatment of cerebral tumour.
Non-specific immunostimulation by FCA or BCG has also been reported to have no effect on i.c. tumour growth (Scheinberg et al.,: 1962; Albright et al., 1975) .-On the-other hand, specific immunotherapy given before i.c. injection of tumour cells does inhibit their growth (Medawar, 1948; Denlinger et al., 1975; Scheinberg et al., 1962; Albright et al., 1975) , and the induction of tumours by methylcholanthrene, as well as the incidence of spontaneous tumours, is dedecreased by pre-immunization with tumour plus an adjuvant (Whitmire and Huebner, 1972; Likhite, 1976) .
We therefore conclude that C. parvum therapy alone has little effect on i.c. tumour growth in mice. A few patients who received C. parvum therapy developed brain metastases (Castro and Osborn, (in prepn.) ) and therefore, it is probable that this vaccine has a similarly poor effect in man.
